|
US5814464A
(en)
*
|
1994-10-07 |
1998-09-29 |
Regeneron Pharma |
Nucleic acids encoding TIE-2 ligand-2
|
|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
|
HUP0001261A3
(en)
*
|
1997-04-30 |
2001-11-28 |
Univ Washington Seattle |
Method of imaging cell death in vivo
|
|
US20040185039A1
(en)
*
|
2002-08-30 |
2004-09-23 |
Heinz Kohler |
Therapeutic applications of noncovalent dimerizing antibodies
|
|
US20050033033A1
(en)
*
|
1998-05-04 |
2005-02-10 |
Heinz Kohler |
Trans-membrane-antibody induced inhibition of apoptosis
|
|
US7569674B2
(en)
*
|
1998-05-04 |
2009-08-04 |
Innexus Biotechnology International Limited |
Autophilic antibodies
|
|
US6300308B1
(en)
|
1997-12-31 |
2001-10-09 |
Board Of Regents, The University Of Texas System |
Methods and compositions for inducing autoimmunity in the treatment of cancers
|
|
US20090208418A1
(en)
*
|
2005-04-29 |
2009-08-20 |
Innexus Biotechnology Internaltional Ltd. |
Superantibody synthesis and use in detection, prevention and treatment of disease
|
|
US6406693B1
(en)
*
|
1998-07-13 |
2002-06-18 |
Board Of Regents, The University Of Texas System |
Cancer treatment methods using antibodies to aminophospholipids
|
|
EP1520588B1
(en)
|
1998-07-13 |
2014-12-24 |
Board Of Regents, The University Of Texas System |
Uses of antibodies to aminophospholipids for cancer treatment
|
|
US7067109B1
(en)
|
1998-07-13 |
2006-06-27 |
Board Of Regents, The University Of Texas System |
Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids
|
|
US6818213B1
(en)
*
|
1998-07-13 |
2004-11-16 |
Board Of Regents, The University Of Texas System |
Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
|
|
ATE276763T1
(de)
*
|
1998-07-13 |
2004-10-15 |
Univ Texas |
Verwendung von antikörper gegen aminophospholipide zur krebsbehandlung
|
|
US6361774B1
(en)
*
|
1999-09-17 |
2002-03-26 |
Immunomedics, Inc. |
Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
|
|
US20050197283A1
(en)
*
|
1998-10-04 |
2005-09-08 |
Vascular Biogenics Ltd. |
Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease
|
|
IL126447A
(en)
*
|
1998-10-04 |
2004-09-27 |
Vascular Biogenics Ltd |
An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
|
|
US6602274B1
(en)
*
|
1999-01-15 |
2003-08-05 |
Light Sciences Corporation |
Targeted transcutaneous cancer therapy
|
|
US6521424B2
(en)
*
|
1999-06-07 |
2003-02-18 |
Immunex Corporation |
Recombinant expression of Tek antagonists
|
|
EP1254181B1
(en)
*
|
1999-08-30 |
2006-10-25 |
WesaGen, Inc |
Diagnostic assay for type 2 heparin-induced thrombocytopenia
|
|
US6777439B2
(en)
*
|
2000-05-30 |
2004-08-17 |
Advanced Research & Technology Institute, Inc. |
Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways
|
|
US7445802B2
(en)
*
|
2000-12-26 |
2008-11-04 |
Yeda Research And Development Co. Ltd |
Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-sensitive diseases
|
|
US20040001839A1
(en)
*
|
2000-12-29 |
2004-01-01 |
Avigdor Levanon |
Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
|
|
US20040001822A1
(en)
*
|
2000-12-29 |
2004-01-01 |
Avigdor Levanon |
Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
|
|
US7132510B2
(en)
*
|
2000-12-29 |
2006-11-07 |
Bio-Technology General (Israel) Ltd. |
Specific human antibodies for selective cancer therapy
|
|
US20040002450A1
(en)
*
|
2000-12-29 |
2004-01-01 |
Janette Lazarovits |
Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US7635680B2
(en)
|
2001-02-21 |
2009-12-22 |
Alavita Pharmaceuticals, Inc. |
Attenuation of reperfusion injury
|
|
US20090291086A1
(en)
*
|
2001-02-21 |
2009-11-26 |
Alavita Pharmaceuticals, Inc. |
Compositions and Methods for Treating Cerebral Thrombosis and Global Cerebral Ischemia
|
|
US6962903B2
(en)
*
|
2001-02-21 |
2005-11-08 |
Alavita, Inc. |
Modified annexin proteins and methods for preventing thrombosis
|
|
US7635676B2
(en)
|
2001-02-21 |
2009-12-22 |
Alavita Pharmaccuticals, Inc. |
Modified annexin proteins and methods for their use in organ transplantation
|
|
US7645739B2
(en)
|
2001-02-21 |
2010-01-12 |
Alavita Pharmaceuticals, Inc. |
Modified annexin compositions and methods of using same
|
|
JP2004535375A
(ja)
*
|
2001-04-03 |
2004-11-25 |
テセウス イメージング コーポレーション |
生体内における細胞死の検出および随伴する症状の治療のためのアネキシンの使用方法
|
|
EP1381839A4
(en)
*
|
2001-04-03 |
2005-10-12 |
Univ Leland Stanford Junior |
METHOD FOR THE IMAGE OF CELL DEOD IN VIVO
|
|
US20050013778A1
(en)
*
|
2001-04-03 |
2005-01-20 |
Theseus Imaging Corporation |
Methods and compositions for predicting the response to a therapeutic regimen in a subject having a disease associated with cell death
|
|
DE10127712A1
(de)
*
|
2001-06-07 |
2002-12-19 |
Torsten Witte |
Anwendung von IgM-Antikörpern gegen dsDNA beim systemischen Lupus erythematodes mit Nephritis
|
|
US6763760B2
(en)
*
|
2001-07-03 |
2004-07-20 |
Hansen Conly L |
Machine for injecting liquids
|
|
DE10145254A1
(de)
*
|
2001-09-13 |
2003-04-10 |
November Ag Molekulare Medizin |
Verwendung eines Proteins zur Herstellung eines Medikaments zur Stimulierung einer inflammatorischen zellulären Immunantwort
|
|
WO2003028840A2
(en)
*
|
2001-09-27 |
2003-04-10 |
Board Of Regents, The University Of Texas System |
Combined compositions and methods for tumor vasculature coagulation and treatment
|
|
ATE295155T1
(de)
*
|
2001-10-05 |
2005-05-15 |
Surmodics Inc |
Beschichtungen mit immobilisierten partikeln sowie verwendungen derselben
|
|
US7261875B2
(en)
|
2001-12-21 |
2007-08-28 |
Board Of Regents, The University Of Texas System |
Dendritic poly (amino acid) carriers and methods of use
|
|
JP4242590B2
(ja)
*
|
2002-01-11 |
2009-03-25 |
俊一 塩澤 |
慢性関節リウマチの疾患感受性遺伝子、及びその利用
|
|
US20030133938A1
(en)
*
|
2002-01-15 |
2003-07-17 |
Penichet Manuel L. |
Antibody-avidin fusion proteins as cytotoxic drugs
|
|
US6982154B2
(en)
*
|
2002-02-21 |
2006-01-03 |
Surromed, Inc. |
Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease
|
|
US9745380B2
(en)
*
|
2002-03-01 |
2017-08-29 |
Immunomedics, Inc. |
RS7 antibodies
|
|
US20040022731A1
(en)
*
|
2002-04-26 |
2004-02-05 |
Alexei Bogdanov |
In vivo imaging of apoptosis
|
|
AU2003273176A1
(en)
*
|
2002-05-17 |
2003-12-12 |
Board Of Regents, The University Of Texas System |
Beta-2-glycoprotein 1 is an inhibitor of angiogenesis
|
|
AU2003237870A1
(en)
*
|
2002-06-07 |
2003-12-22 |
The Brigham & Women's Hospital, Inc. |
Method and composition for inhibing or slowing blood coagulation
|
|
US20040208877A1
(en)
*
|
2002-07-01 |
2004-10-21 |
Avigdor Levanon |
Antibodies and uses thereof
|
|
AU2003279657A1
(en)
*
|
2002-07-01 |
2004-01-19 |
Savient Pharmaceuticals, Inc. |
Compositions and methods for therapeutic treatment
|
|
US20040202665A1
(en)
*
|
2002-07-01 |
2004-10-14 |
Janette Lazarovits |
Compositions and methods for therapeutic treatment
|
|
US7678386B2
(en)
*
|
2002-07-15 |
2010-03-16 |
Board Of Regents The University Of Texas |
Liposomes coated with selected antibodies that bind to aminophospholipids
|
|
US7611704B2
(en)
|
2002-07-15 |
2009-11-03 |
Board Of Regents, The University Of Texas System |
Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids
|
|
US7384909B2
(en)
|
2002-07-15 |
2008-06-10 |
Board Of Regents, The University Of Texas System |
Anti-viral treatment methods using phosphatidylethanolamine-binding peptides linked to anti-viral agents
|
|
US7615223B2
(en)
*
|
2002-07-15 |
2009-11-10 |
Board Of Regents, The University Of Texas System |
Selected immunoconjugates for binding to aminophospholipids
|
|
US7511124B2
(en)
|
2002-07-15 |
2009-03-31 |
Board Of Regents, The University Of Texas System |
Compositions comprising phosphatidylethanolamine-binding peptides linked to anti-viral agents
|
|
US7879801B2
(en)
|
2002-07-15 |
2011-02-01 |
Board Of Regents, The University Of Texas System |
Compositions comprising cell-impermeant duramycin derivatives
|
|
EP2357009A1
(en)
*
|
2002-07-15 |
2011-08-17 |
Board of Regents, The University of Texas System |
Duramycin peptide binding to anionic phospholipids and aminophospholipids conjugates and their use in treating viral infections
|
|
US7247303B2
(en)
*
|
2002-07-15 |
2007-07-24 |
Board Of Regents, The University Of Texas System |
Selected antibody CDRs for binding to aminophospholipids
|
|
US20040131622A1
(en)
*
|
2002-07-15 |
2004-07-08 |
Board Of Regents |
Combinations and kits for treating viral infections using immunoconjugates to aminophospholipids
|
|
US7906115B2
(en)
*
|
2002-07-15 |
2011-03-15 |
Thorpe Philip E |
Combinations kits and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids
|
|
US7378386B2
(en)
|
2002-07-15 |
2008-05-27 |
Board Of Regents, The University Of Texas System |
Anti-viral treatment methods using phosphatidylethanolamine-binding peptide derivatives
|
|
US7625563B2
(en)
*
|
2002-07-15 |
2009-12-01 |
Board Of Regents, The University Of Texas System |
Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids
|
|
US7714109B2
(en)
*
|
2002-07-15 |
2010-05-11 |
Board Of Regents, The University Of Texas System |
Combinations and kits for cancer treatment using selected antibodies to aminophospholipids
|
|
US7455833B2
(en)
|
2002-07-15 |
2008-11-25 |
Board Of Regents, The University Of Texas System |
Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids
|
|
US7572448B2
(en)
*
|
2002-07-15 |
2009-08-11 |
Board Of Regents, The University Of Texas System |
Combined cancer treatment methods using selected antibodies to aminophospholipids
|
|
US7790159B2
(en)
*
|
2002-07-15 |
2010-09-07 |
Board Of Regents, The University Of Texas System |
Methods, combinations and kits for treating viral infections using immunoconjugates and antibodies to aminophospholipids
|
|
US7622118B2
(en)
*
|
2002-07-15 |
2009-11-24 |
Board Of Regents, The University Of Texas System |
Cancer treatment methods using selected antibodies to aminophospholipids
|
|
WO2004013303A2
(en)
*
|
2002-08-02 |
2004-02-12 |
Surromed, Inc. |
Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease
|
|
US20040042959A1
(en)
*
|
2002-08-28 |
2004-03-04 |
Michael Montalto |
Imaging cell death in vivo using non-radionuclide contrast agents
|
|
US9701754B1
(en)
|
2002-10-23 |
2017-07-11 |
City Of Hope |
Covalent disulfide-linked diabodies and uses thereof
|
|
US20040191215A1
(en)
*
|
2003-03-25 |
2004-09-30 |
Michael Froix |
Compositions for induction of a therapeutic response
|
|
KR101424624B1
(ko)
|
2003-05-14 |
2014-07-31 |
이뮤노젠 아이엔씨 |
약물 콘쥬게이트 조성물
|
|
US20110002978A1
(en)
|
2003-06-17 |
2011-01-06 |
Harrison Roger G |
Enzyme prodrug cancer therapy selectively targeted to tumor cells or tumor vasculature and methods of production and use thereof
|
|
US20070207158A1
(en)
*
|
2003-06-17 |
2007-09-06 |
Harrison Roger G |
Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof
|
|
NZ543495A
(en)
|
2003-06-25 |
2009-04-30 |
Peregrine Pharmaceuticals Inc |
Method and apparatus for continuous large-scale radiolabeling of proteins
|
|
US20050069955A1
(en)
*
|
2003-06-30 |
2005-03-31 |
Daniel Plaksin |
Antibodies and uses thereof
|
|
US7771956B2
(en)
*
|
2003-06-30 |
2010-08-10 |
Brigham & Women's Hospital, Inc. |
Method for detecting the presence of a phospholipid
|
|
US20050152906A1
(en)
*
|
2003-06-30 |
2005-07-14 |
Avigdor Levanon |
Specific human antibodies
|
|
DE10338733A1
(de)
*
|
2003-08-22 |
2005-03-24 |
Berdel, Wolfgang E., Prof. Dr.med. |
Fusionspolypeptide und deren Verwendung für die antivaskuläre Tumortherapie
|
|
WO2005069935A2
(en)
*
|
2004-01-20 |
2005-08-04 |
University Of Medicine And Dentistry Of New Jersey |
METHODS FOR MEASURING TRANSFORMING GROWTH FACTOR BETA (TGF-β) RECEPTOR SIGNALING ACTIVITY AND USES THEREOF
|
|
WO2005079831A1
(en)
*
|
2004-02-13 |
2005-09-01 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Use of hcnp peptides for the modulation of cardio-vascular physiology and diuresis
|
|
EP1734983A4
(en)
*
|
2004-03-11 |
2009-11-18 |
Alavita Pharmaceuticals Inc |
MODIFIED ANNEXINE PROTEINS AND METHODS FOR PREVENTING THROMBOSIS
|
|
US20060003020A1
(en)
*
|
2004-03-11 |
2006-01-05 |
The Regents Of The University Of Michigan |
Anti-metastatic ability of mibefradil and gadolinium
|
|
WO2005115477A2
(en)
|
2004-04-13 |
2005-12-08 |
Quintessence Biosciences, Inc. |
Non-natural ribonuclease conjugates as cytotoxic agents
|
|
WO2005117848A2
(en)
*
|
2004-06-02 |
2005-12-15 |
Sidney Kimmel Cancer Center |
Vascular targets for detecting, imaging and treating neoplasia or neovasculature
|
|
US20050271726A1
(en)
*
|
2004-06-02 |
2005-12-08 |
Albert Crum |
Immune enhancing compositions and methods of use thereof
|
|
TW200600784A
(en)
*
|
2004-06-02 |
2006-01-01 |
Sidney Kimmel Cancer Ct |
Imaging and therapeutic agents targeting proteins expressed on endothelial cell surface
|
|
US7511016B2
(en)
*
|
2004-07-07 |
2009-03-31 |
Mosamedix B.V. |
Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof
|
|
US8697139B2
(en)
|
2004-09-21 |
2014-04-15 |
Frank M. Phillips |
Method of intervertebral disc treatment using articular chondrocyte cells
|
|
US20060127311A1
(en)
*
|
2004-11-17 |
2006-06-15 |
Duke University |
Radiation dosimetry and blocking antibodies and methods and uses therefor in the treatment of cancer
|
|
US20080119367A1
(en)
*
|
2004-12-17 |
2008-05-22 |
Mayo Foundation For Medical Education And Research |
Prognosis of Renal Cell Carcinoma
|
|
BRPI0519596B1
(pt)
|
2004-12-21 |
2022-01-18 |
Astrazeneca Ab |
Agente de ligação alvejado, anticorpo monoclonal que se liga a angiopoietina-2, molécula de ácido nucleico, vetor, e, uso do agente de ligação alvejado
|
|
DK1853631T3
(en)
*
|
2005-01-24 |
2016-03-29 |
Univ Texas |
Fc-FUSION CONSTRUCTIONS BINDING TO PHOSPHATIDYLSERINE AND THERAPEUTIC APPLICATION THEREOF
|
|
CA2597407C
(en)
|
2005-02-11 |
2013-09-10 |
Immunogen, Inc. |
Process for preparing stable drug conjugates
|
|
US7393833B2
(en)
|
2005-03-09 |
2008-07-01 |
The Board Of Regents Of The University Of Oklahoma |
Chimeric proteins with phosphatidylserine binding domains
|
|
EP1712241A1
(en)
*
|
2005-04-15 |
2006-10-18 |
Centre National De La Recherche Scientifique (Cnrs) |
Composition for treating cancer adapted for intra-tumoral administration and uses thereof
|
|
WO2006109312A2
(en)
*
|
2005-04-15 |
2006-10-19 |
Vascular Biogenics Ltd. |
Compositions containing beta 2-glycoprotein i-derived peptides for the prevention and/or treatment of vascular disease
|
|
US20060257317A1
(en)
*
|
2005-05-04 |
2006-11-16 |
Duke University |
Combination therapy in the treatment of cancer
|
|
HRP20140338T1
(hr)
|
2005-07-25 |
2014-06-20 |
Emergent Product Development Seattle, Llc |
Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20
|
|
WO2007019232A2
(en)
|
2005-08-03 |
2007-02-15 |
Immunogen, Inc. |
Immunoconjugate formulations
|
|
EP3539572A1
(en)
|
2005-08-24 |
2019-09-18 |
ImmunoGen, Inc. |
Process for preparing maytansinoid antibody conjugates
|
|
WO2007109321A2
(en)
|
2006-03-20 |
2007-09-27 |
The Regents Of The University Of California |
Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
|
|
US20070225213A1
(en)
*
|
2006-03-23 |
2007-09-27 |
Kosak Matthew K |
Nucleic acid carriers for delivery of therapeutic agents
|
|
WO2007117432A2
(en)
*
|
2006-03-30 |
2007-10-18 |
The Regents Of The University Of Michigan |
Methods and compositions for modulating angiogenesis and tumor growth
|
|
US9789161B2
(en)
*
|
2006-04-28 |
2017-10-17 |
Warsaw Orthopedic, Inc. |
Methods for treating back or neck pain caused by NGF using a therapeutic agent consisting of ReN-1820, ALE-0540 and capsaicin
|
|
US20080138334A1
(en)
*
|
2006-05-31 |
2008-06-12 |
Sabbadini Roger A |
Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same
|
|
US8796429B2
(en)
*
|
2006-05-31 |
2014-08-05 |
Lpath, Inc. |
Bioactive lipid derivatives, and methods of making and using same
|
|
US9274130B2
(en)
|
2006-05-31 |
2016-03-01 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to lysophosphatidic acid
|
|
US9274129B2
(en)
*
|
2006-05-31 |
2016-03-01 |
Lpath, Inc. |
Methods and reagents for detecting bioactive lipids
|
|
WO2007146968A2
(en)
|
2006-06-12 |
2007-12-21 |
Trubion Pharmaceuticals, Inc. |
Single-chain multivalent binding proteins with effector function
|
|
EP2044097A4
(en)
*
|
2006-06-23 |
2010-10-06 |
Quintessence Biosciences Inc |
Modified ribonucleases
|
|
US8298801B2
(en)
|
2006-07-17 |
2012-10-30 |
Quintessence Biosciences, Inc. |
Methods and compositions for the treatment of cancer
|
|
EP2862579B1
(en)
|
2006-10-04 |
2017-05-17 |
Dana-Farber Cancer Institute, Inc. |
Tumor immunity
|
|
US8518870B2
(en)
*
|
2007-02-19 |
2013-08-27 |
The Board Of Regents Of The University Of Oklahoma |
Compositions and methods for cancer treatment using targeted carbon nanotubes
|
|
US9504745B2
(en)
|
2007-02-19 |
2016-11-29 |
The Board Of Regents Of The University Of Oklahoma |
Compositions and methods for cancer treatment using targeted carbon nanotubes
|
|
US10745701B2
(en)
|
2007-06-28 |
2020-08-18 |
The Trustees Of Princeton University |
Methods of identifying and treating poor-prognosis cancers
|
|
US20090324596A1
(en)
*
|
2008-06-30 |
2009-12-31 |
The Trustees Of Princeton University |
Methods of identifying and treating poor-prognosis cancers
|
|
US8334239B2
(en)
|
2007-07-10 |
2012-12-18 |
The Board Of Regents Of The University Of Texas System |
High affinity VEGF-receptor antagonists
|
|
US8940298B2
(en)
|
2007-09-04 |
2015-01-27 |
The Regents Of The University Of California |
High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
|
|
KR20100065190A
(ko)
*
|
2007-09-14 |
2010-06-15 |
닛토덴코 가부시키가이샤 |
약물 담체
|
|
EP2205271B1
(en)
*
|
2007-10-08 |
2014-05-21 |
Quintessence Biosciences, Inc. |
Compositions and methods for ribonuclease-based therapies
|
|
ES2572356T3
(es)
|
2007-11-09 |
2016-05-31 |
Peregrine Pharmaceuticals Inc |
Composiciones de anticuerpos dirigidos contra VEGF y procedimientos
|
|
AU2009203562A1
(en)
*
|
2008-01-07 |
2009-07-16 |
Patrys Limited |
BARB4 target which comprises TATA-binding protein-associated factor 15, antibody designated BARB4, BARB4 related antibodies, and methods of making and using same
|
|
EP2365003A1
(en)
|
2008-04-11 |
2011-09-14 |
Emergent Product Development Seattle, LLC |
CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
|
WO2009127046A1
(en)
*
|
2008-04-14 |
2009-10-22 |
Proscan Rx Pharma Inc. |
Prostate specific membrane antigen antibodies and antigen binding fragments
|
|
US8029782B2
(en)
|
2008-10-01 |
2011-10-04 |
Quintessence Biosciences, Inc. |
Therapeutic ribonucleases
|
|
EP2398504B1
(en)
|
2009-02-17 |
2018-11-28 |
Cornell Research Foundation, Inc. |
Methods and kits for diagnosis of cancer and prediction of therapeutic value
|
|
EP2229951A1
(en)
|
2009-03-08 |
2010-09-22 |
Stichting Katholieke Universiteit |
Methods for the treatment or prevention of systemic sclerosis
|
|
BRPI1010620B8
(pt)
|
2009-06-03 |
2021-05-25 |
Immunogen Inc |
métodos de conjugação
|
|
CA2782333C
(en)
|
2009-12-02 |
2019-06-04 |
Imaginab, Inc. |
J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
|
|
BR112012029611A2
(pt)
*
|
2010-05-21 |
2017-07-25 |
Merrimack Pharmaceuticals Inc |
proteína de fusão biespecífica, composição farmacêutica, método de tratamento de dano ao tecido em um indivíduo, método de promoção da regeração ou sobrevivência do tecido em um indivíduo e molécula de ácido nucleico
|
|
RS58367B1
(sr)
|
2011-03-29 |
2019-03-29 |
Immunogen Inc |
Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
|
|
WO2014055877A1
(en)
|
2012-10-04 |
2014-04-10 |
Immunogen, Inc. |
Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
|
|
PT3524617T
(pt)
*
|
2013-03-15 |
2023-07-12 |
Gladiator Biosciences Inc |
Domínios gla como agentes terapêuticos
|
|
US9987241B2
(en)
|
2014-09-25 |
2018-06-05 |
The Board Of Regents Of The University Of Oklahoma |
Enzyme conjugate and prodrug cancer therapy
|
|
WO2016081637A1
(en)
*
|
2014-11-18 |
2016-05-26 |
Maximum Fidelity Surgica Simulations, Llc |
Post mortem reconstitution of circulation
|
|
WO2016090157A1
(en)
|
2014-12-04 |
2016-06-09 |
Celgene Corporation |
Biomolecule conjugates
|
|
WO2017027325A1
(en)
|
2015-08-07 |
2017-02-16 |
Imaginab, Inc. |
Antigen binding constructs to target molecules
|
|
EP3352760B1
(en)
|
2015-09-21 |
2026-03-11 |
Aptevo Research and Development LLC |
Cd3 binding polypeptides
|
|
CN115960249A
(zh)
|
2015-10-02 |
2023-04-14 |
银溪制药股份有限公司 |
用于组织修复的双特异性治疗性蛋白质
|
|
PT3380525T
(pt)
|
2015-11-25 |
2024-02-05 |
Immunogen Inc |
Formulações farmacêuticas e métodos que as utilizam
|
|
WO2018053597A1
(en)
|
2016-09-23 |
2018-03-29 |
Csl Limited |
Coagulation factor binding proteins and uses thereof
|
|
US11180535B1
(en)
|
2016-12-07 |
2021-11-23 |
David Gordon Bermudes |
Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
|
|
WO2018147960A1
(en)
|
2017-02-08 |
2018-08-16 |
Imaginab, Inc. |
Extension sequences for diabodies
|
|
CA3063324A1
(en)
|
2017-05-16 |
2018-11-22 |
Bhami's Research Laboratory, Pvt. Ltd. |
High concentration protein formulations with reduced viscosity
|
|
CA3070230A1
(en)
|
2017-07-24 |
2019-01-31 |
Rutgers, The State University Of New Jersey |
Phosphatidylserine targeting fusion molecules and methods for their use
|
|
WO2020032951A1
(en)
|
2018-08-09 |
2020-02-13 |
The Board Of Regents Of The University Of Oklahoma |
Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same
|
|
SG11202001535RA
(en)
|
2017-09-05 |
2020-03-30 |
Gladiator Biosciences Inc |
Method of targeting exosomes
|
|
PE20200719A1
(es)
|
2017-11-13 |
2020-07-21 |
Maximum Fidelity Surgical Simulations Llc |
Reconstitucion de la circulacion posmortem, metodos y procedimientos especializados
|
|
US11716989B2
(en)
|
2019-04-16 |
2023-08-08 |
Maximum Fidelity Surgical Simulations, LLC |
Cadaver preservation systems and methods
|
|
US11915610B2
(en)
|
2019-05-15 |
2024-02-27 |
Maximum Fidelity Surgical Simulations, LLC |
Cadaverous heart model
|
|
US12433876B2
(en)
|
2019-08-30 |
2025-10-07 |
University Of Rochester |
Septin inhibitors for treatment of cancers
|
|
JP2024511277A
(ja)
|
2021-02-19 |
2024-03-13 |
メビオン・メディカル・システムズ・インコーポレーテッド |
粒子線治療システムのためのガントリー
|
|
CN114807032B
(zh)
*
|
2022-05-20 |
2023-09-12 |
南京大学 |
地塞米松诱导中性粒细胞产生的细胞外囊泡在制备治疗消炎药物中的应用
|
|
WO2025027529A1
(en)
|
2023-07-31 |
2025-02-06 |
Advesya |
Anti-il-1rap antibody drug conjugates and methods of use thereof
|
|
TW202530255A
(zh)
|
2023-12-15 |
2025-08-01 |
法商亞維西亞有限公司 |
抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物
|